Clinical metabolomics of exhaled breath condensate in chronic respiratory diseases

Mauro Maniscalco, Salvatore Fuschillo, Debora Paris, Adele Cutignano, Alessandro Sanduzzi, Andrea Motta

Research output: Contribution to journalReview articlepeer-review


Chronic respiratory diseases (CRDs) are complex multifactorial disorders involving the airways and other lung structures. The development of reliable markers for an early and accurate diagnosis, including disease phenotype, and prediction of the response and/or adherence to treatment prescribed are essential points for the correct management of CRDs. Beside the traditional techniques to detect biomarkers, "omics" sciences have stimulated interest in clinical field as they could potentially improve the study of disease phenotype. Perturbations in a variety of metabolic and signaling pathways could contribute an understanding of CRDs pathogenesis. In particular, metabolomics provides powerful tools to map biological perturbations and their relationship with disease pathogenesis. The exhaled breath condensate (EBC) is a natural matrix of the respiratory tract, and is well suited for metabolomics studies. In this article, we review the current state of metabolomics methodology applied to EBC in the study of CRDs.

Original languageEnglish
Pages (from-to)121-149
Number of pages29
JournalAdvances in Clinical Chemistry
Publication statusPublished - Jan 8 2019


  • Animals
  • Asthma/diagnosis
  • Biomarkers/analysis
  • Breath Tests/methods
  • Ciliary Motility Disorders/diagnosis
  • Cystic Fibrosis/diagnosis
  • Humans
  • Lung Neoplasms/diagnosis
  • Magnetic Resonance Spectroscopy/methods
  • Mass Spectrometry/methods
  • Metabolomics/methods
  • Pulmonary Disease, Chronic Obstructive/diagnosis


Dive into the research topics of 'Clinical metabolomics of exhaled breath condensate in chronic respiratory diseases'. Together they form a unique fingerprint.

Cite this